Related Experiment Video

Updated: Jun 19, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

Cornelia M Ulrich1, Jeannette Bigler, John D Potter

  • 1Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA. nulrich@fhcrc.org

Nature Reviews. Cancer
|February 24, 2006
PubMed

Insights

Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) show promise in cancer prevention, but cardiovascular risks and genetic factors necessitate personalized strategies for effective chemoprevention.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, are recognized for their chemopreventive potential against various cancers.
  • NSAIDs target cyclooxygenase (COX) enzymes, but specific inhibition of cyclooxygenase 2 (COX-2) has raised concerns regarding cardiovascular toxicity.

Purpose of the Study:

  • To evaluate the chemopreventive efficacy of NSAIDs.
  • To address the potential cardiovascular risks associated with NSAID use.
  • To explore the role of individual genetic factors in determining the success of NSAID chemoprevention.

Main Methods:

  • Review of existing studies on NSAID chemoprevention.
  • Analysis of research on NSAID-induced cardiovascular toxicity.
  • Investigation into genetic predispositions influencing NSAID efficacy and safety.

Main Results:

  • NSAIDs demonstrate promise in preventing cancers of the colon, stomach, breast, and lung.
  • Specific COX-2 inhibiting NSAIDs are associated with increased cardiovascular risks.
  • Inherited genetic characteristics may significantly influence the effectiveness of chemopreventive strategies.

Conclusions:

  • While NSAIDs hold chemopreventive promise, their use requires careful consideration of cardiovascular risks.
  • Personalized chemoprevention strategies, accounting for individual medical history and genetic makeup, are crucial for optimizing efficacy and minimizing adverse effects.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...